Urinary Tract InfectionsPer-UTINCT05826067
Study of E. Coli Isolates From Recurrent Urinary Tract Infections
An observational study of Urinary Tract Infections and Patients With Suprabubic Catheter, run by Université Catholique de Louvain at 1 site in Belgium.
Trial summary
Prospective study aiming at collecting clinical Escherichia coli isolates from patients with recurrent urinary tract infection; samples to be collected during routine procedures. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Urinary Tract Infections, Patients With Suprabubic Catheter, Patients With Nephrostomy Catheter
- What is being tested?
- collection of bacterial strains
- How many people
- 45 participants
- Where
- 1 siteBelgium
- Study dates
- 20 Apr 2023to 31 Dec 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: ambulatory patients coming to the hospital for a visit to the nephrology department or patients hospitalized in nephrology department
Who may be able to join
- patients hospitalized for urinary tract infection, with or without neurological disorders (spina bifida, MS, paraplegic patients) or ambulatory patients diagnosed with a urinary tract infection when the identified causative agent is E. coli
- patients who have or are planned to undergo the insertion of a suprapubic catheter
- patients who have or are planned to undergo the insertion a nephrostomy catheter
Who cannot join
- refusing the planned treatment
- with therapy compliance
- pregnant women
- who do not consent to participate
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Belgium1 site, 1 recruiting
- Recruiting
Cliniques universitaires Saint Luc
Brussels, 1200
Jean Cyr Yombi
About this study
Official title: Systematic Analysis of Bacterial Multidrug Tolerance in Longitudinal Isolates of Patients That Are Prone to Developing Urinary Tract Infections
Prospective study aiming at collecting clinical Escherichia coli isolates from patients with recurrent urinary tract infection; samples to be collected during routine procedures.
Read the detailed description
In a clinical context, persisters are of potential concern as they perpetuate chronic infections and enhance the development of antibiotic resistance. Novel therapeutic strategies to combat persisters are therefore highly needed. Most mechanistic studies on persistence to date deal with lab strains. The main goal of this project is to define principles of persistence and its evolution in natural strains of E. coli isolated from patients. Isolates will be collected as follows, from three types of patients corresponding to 3 different clinical situations where recurrent infection is likely
(A) Patients with urinary tract infection caused by E. coli, with or without neurological disorders.
First visit : for patients suspected for UTI, a first urine sample is collected (as part of the routine diagnosis procedure for this type of infection), before starting any antibiotic treatment. Likewise, a blood sample is taken to establish a possible concomitant sepsis if considered useful by the doctor. If the diagnosis of UTI is confirmed, informed consent will be obtained after explanation of the study by the investigator, making clear that the patient will be included only if E. coli is isolated from the urine. If the patient agrees to participate, the samples will be stored at -80°C for further analysis. Using a standardized questionnaire, a detailed medical history concerning recent UTIs and antibiotics taken by the patients is composed, possibly with the help of the family doctor of the patient if he/she does agree.
Next visits: If the patients come back for another episode (at least 2 weeks after the end of the treatment for the previous episode has been resolved), or for a control visit, data concerning their recent UTI history and antibiotic use will be collected using standardized questionnaires. A new urine sample will be collected. If the patients consult their GP for a new episode, they will be asked to fill the form with their GP and instruct the lab where the analysis of the new sample is done to send the strain to Saint Luc (cost will be covered). Written instruction will be provided.
IMPORTANT: The collection of urine samples for this study will not impede SOC. Samples are taken following the protocols used for patients with UTIs (and sepsis). The antibiotic regimen will not be adapted based on these results. When signing the informed consent, the patients will be informed that they will not personally benefit from the study but help scientific research.
(B-C) Patients that are planned to undergo the insertion of a suprapubic or nephrostomy catheter.
Visit 1 These patients are seen at the ward or consultation for a variety of non-UTI related problems. During this visit, informed consent is obtained and the study is explained by the investigator. Using a standardized questionnaire, a detailed medical history concerning recent UTIs and antibiotics taken by the patients is composed possibly with the help of the family doctor of the patient if he/she does agree. A first urine sample is collected.
Visit 2 (if not performed in visit 1) Insertion of the catheter and collection of a new urine sample (again, this is part of standard of care and not a study procedure).
Next visits Regular exchange of the catheter, every 6 weeks at the urology department. During these visits, patients are asked about their recent UTI history and any antibiotic use. Prior to the exchange, a urine sample is taken and the tip of the old catheter is collected (as per standard of care). Isolates from urine will be frozen and tips of catheter will be processed for biofilm disruption and freezing of bacteria.
IMPORTANT: The collection of urine samples for this study will not impede SOC. Samples are taken following the protocols used for patients with UTIs (and sepsis). The antibiotic regimen (if any) will not be adapted based on these results. When signing the informed consent, the patients will be informed that they will not personally benefit from the study but help scientific research.
Patients will be recruited over a two years period. For each patient, the duration of the participation will correspond (A) to each episode of UTI with sepsis over that period of time and (B-C) to the period during which a catheter remains in place over the study period.
Directly after collection, biofilms on catheter tips will be disrupted following in-house protocols For both urine samples and catheter tip biofilms, bacterial strains will be isolated by inoculating on selective agar plates (MacConkey, mannitol salt, cetrimide …), followed by aerobic incubation at 37°C for 24h. Bacterial isolates observed on the selective media plates will be aseptically subcultured onto freshly prepared media plates and subjected to identification. For patients suffering from recurrent UTIs, the investigators expect to find mainly Escherichia coli while for patients with a suprapubic catheter the investigators expect mainly E. coli, as well as Pseudomonas aeruginosa, Proteus mirabilis and Klebsiella pneumoniae strains. Only E. coli will be stored for the study.
Isolates will then be transferred to research lab of the sponsor for further molecular analysis (determination of persister character in the presence of antibiotic, WGS, essentially).
- Conditions
- Urinary Tract Infections, Patients With Suprabubic Catheter, Patients With Nephrostomy Catheter
- Being tested
- collection of bacterial strains
- Keywords
- Urinary tract infection, Escherichia coli
- Medical subject headings
- Urinary Tract Infections, Escherichia coli Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
collection of bacterial strainsOther
Urine (and blood) samples will be collected following SOC procedures for diagnostic purposes, at each visit of the patient (initial visit, follow up study or visit for new episode. For patients needing a catheter, urine sample will be collected before the insertion of the catheter, and before renewal of the catheter. Catheter tips will also be collected and sonicated to isolate bacteria. E. coli will be stored for analysis.
| Study group | Role | What they receive |
|---|---|---|
| patients with UTI or catheter (suprapubic, nephrostomy) | Patients with urinary tract infection caused by E. coli, with or without neurological disorders or patients that are planned to undergo the insertion of a suprapubic or nephrostomy catheter. Receives: Other: collection of bacterial strains |
What is being measured
The primary outcome is the main question the study is designed to answer.
collection of longitudinal E. coli to be used for fundamental research
To collect longitudinal bacterial isolates of E. coli and to record clinical data for fundamental research about patients that are prone to developing urinary tract infections.
Measured: collection till the end of 2024
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Apr 2023
- Study start20 Apr 2023
- Primary completion31 Dec 2025 (estimated)
- Study completion31 Dec 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Urinary Tract InfectionsStudies of the same condition, open and under way.
- More trials run by Université Catholique de LouvainThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 45 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Université Catholique de Louvain
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05826067
- Sponsor's protocol ID
- Per-UTI
- Acronym
- Per-UTI
- Status last verified
- Dec 2024
- First submitted
- 11 Apr 2023
- Last updated
- 10 Dec 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Balaban NQ, Helaine S, Lewis K, Ackermann M, Aldridge B, Andersson DI, Brynildsen MP, Bumann D, Camilli A, Collins JJ, Dehio C, Fortune S, Ghigo JM, Hardt WD, Harms A, Heinemann M, Hung DT, Jenal U, Levin BR, Michiels J, Storz G, Tan MW, Tenson T, Van Melderen L, Zinkernagel A. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019 Jul;17(7):441-448. doi: 10.1038/s41579-019-0196-3.
PubMed 30980069
Study at a glance
From the registry record, last updated by the sponsor on 10 Dec 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Systematic Analysis of Bacterial Multidrug Tolerance in Longitudinal Isolates of Patients That Are Prone to Developing Urinary Tract Infections
- ClinicalTrials.gov ID
- NCT05826067
- Acronym / sponsor ID
- Per-UTI / Per-UTI
- Conditions
- Urinary Tract Infections, Patients With Suprabubic Catheter, Patients With Nephrostomy Catheter
- Keywords
- Urinary tract infection, Escherichia coli
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 45 participants (estimated)
- Lead sponsor
- Université Catholique de LouvainUniversity, hospital or other
- Study start
- 20 Apr 2023 (actual)
- Primary completion
- 31 Dec 2025 (estimated)
- Study completion
- 31 Dec 2025 (estimated)
- First posted
- 24 Apr 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prospective study aiming at collecting clinical Escherichia coli isolates from patients with recurrent urinary tract infection; samples to be collected during routine procedures.
Detailed description
In a clinical context, persisters are of potential concern as they perpetuate chronic infections and enhance the development of antibiotic resistance. Novel therapeutic strategies to combat persisters are therefore highly needed. Most mechanistic studies on persistence to date deal with lab strains. The main goal of this project is to define principles of persistence and its evolution in natural strains of E. coli isolated from patients. Isolates will be collected as follows, from three types of patients corresponding to 3 different clinical situations where recurrent infection is likely
(A) Patients with urinary tract infection caused by E. coli, with or without neurological disorders.
First visit : for patients suspected for UTI, a first urine sample is collected (as part of the routine diagnosis procedure for this type of infection), before starting any antibiotic treatment. Likewise, a blood sample is taken to establish a possible concomitant sepsis if considered useful by the doctor. If the diagnosis of UTI is confirmed, informed consent will be obtained after explanation of the study by the investigator, making clear that the patient will be included only if E. coli is isolated from the urine. If the patient agrees to participate, the samples will be stored at -80°C for further analysis. Using a standardized questionnaire, a detailed medical history concerning recent UTIs and antibiotics taken by the patients is composed, possibly with the help of the family doctor of the patient if he/she does agree.
Next visits: If the patients come back for another episode (at least 2 weeks after the end of the treatment for the previous episode has been resolved), or for a control visit, data concerning their recent UTI history and antibiotic use will be collected using standardized questionnaires. A new urine sample will be collected. If the patients consult their GP for a new episode, they will be asked to fill the form with their GP and instruct the lab where the analysis of the new sample is done to send the strain to Saint Luc (cost will be covered). Written instruction will be provided.
IMPORTANT: The collection of urine samples for this study will not impede SOC. Samples are taken following the protocols used for patients with UTIs (and sepsis). The antibiotic regimen will not be adapted based on these results. When signing the informed consent, the patients will be informed that they will not personally benefit from the study but help scientific research.
(B-C) Patients that are planned to undergo the insertion of a suprapubic or nephrostomy catheter.
Visit 1 These patients are seen at the ward or consultation for a variety of non-UTI related problems. During this visit, informed consent is obtained and the study is explained by the investigator. Using a standardized questionnaire, a detailed medical history concerning recent UTIs and antibiotics taken by the patients is composed possibly with the help of the family doctor of the patient if he/she does agree. A first urine sample is collected.
Visit 2 (if not performed in visit 1) Insertion of the catheter and collection of a new urine sample (again, this is part of standard of care and not a study procedure).
Next visits Regular exchange of the catheter, every 6 weeks at the urology department. During these visits, patients are asked about their recent UTI history and any antibiotic use. Prior to the exchange, a urine sample is taken and the tip of the old catheter is collected (as per standard of care). Isolates from urine will be frozen and tips of catheter will be processed for biofilm disruption and freezing of bacteria.
IMPORTANT: The collection of urine samples for this study will not impede SOC. Samples are taken following the protocols used for patients with UTIs (and sepsis). The antibiotic regimen (if any) will not be adapted based on these results. When signing the informed consent, the patients will be informed that they will not personally benefit from the study but help scientific research.
Patients will be recruited over a two years period. For each patient, the duration of the participation will correspond (A) to each episode of UTI with sepsis over that period of time and (B-C) to the period during which a catheter remains in place over the study period.
Directly after collection, biofilms on catheter tips will be disrupted following in-house protocols For both urine samples and catheter tip biofilms, bacterial strains will be isolated by inoculating on selective agar plates (MacConkey, mannitol salt, cetrimide …), followed by aerobic incubation at 37°C for 24h. Bacterial isolates observed on the selective media plates will be aseptically subcultured onto freshly prepared media plates and subjected to identification. For patients suffering from recurrent UTIs, the investigators expect to find mainly Escherichia coli while for patients with a suprapubic catheter the investigators expect mainly E. coli, as well as Pseudomonas aeruginosa, Proteus mirabilis and Klebsiella pneumoniae strains. Only E. coli will be stored for the study.
Isolates will then be transferred to research lab of the sponsor for further molecular analysis (determination of persister character in the presence of antibiotic, WGS, essentially).
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| patients with UTI or catheter (suprapubic, nephrostomy) | – | Other: collection of bacterial strainsPatients with urinary tract infection caused by E. coli, with or without neurological disorders or patients that are planned to undergo the insertion of a suprapubic or nephrostomy catheter. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- ambulatory patients coming to the hospital for a visit to the nephrology department or patients hospitalized in nephrology department
Key inclusion criteria (3 listed)
- patients hospitalized for urinary tract infection, with or without neurological disorders (spina bifida, MS, paraplegic patients) or ambulatory patients diagnosed with a urinary tract infection when the identified causative agent is E. coli
- patients who have or are planned to undergo the insertion of a suprapubic catheter
- patients who have or are planned to undergo the insertion a nephrostomy catheter
Key exclusion criteria (4 listed)
- refusing the planned treatment
- with therapy compliance
- pregnant women
- who do not consent to participate
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| collection of bacterial strainsUrine (and blood) samples will be collected following SOC procedures for diagnostic purposes, at each visit of the patient (initial visit, follow up study or visit for new episode. For patients needing a catheter, urine sample will be collected before the insertion of the catheter, and before renewal of the catheter. Catheter tips will also be collected and sonicated to isolate bacteria. E. coli will be stored for analysis. | Other | patients with UTI or catheter (suprapubic, nephrostomy) |
Primary outcome
collection of longitudinal E. coli to be used for fundamental research
Time frame: collection till the end of 2024
To collect longitudinal bacterial isolates of E. coli and to record clinical data for fundamental research about patients that are prone to developing urinary tract infections.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Dec 2024.
- Background: PubMed 30980069Balaban NQ, Helaine S, Lewis K, Ackermann M, Aldridge B, Andersson DI, Brynildsen MP, Bumann D, Camilli A, Collins JJ, Dehio C, Fortune S, Ghigo JM, Hardt WD, Harms A, Heinemann M, Hung DT, Jenal U, Levin BR, Michiels J, Storz G, Tan MW, Tenson T, Van Melderen L, Zinkernagel A. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019 Jul;17(7):441-448. doi: 10.1038/s41579-019-0196-3.
- Individual participant dataSharing planned: No
Related trials for Urinary Tract Infections
Active, not recruitingPhase 1/2
A Beta-only IL-2 ImmunoTherapY Study
Advanced Solid Tumor, Unresectable Solid Tumor
Recruiting
INterest of the Negative Predictive Value of Integrons in the reduCtion of Large Broad-spectrum anTibiotics Consumption for Urinary Tract infectionS
Drug Resistance, Microbial, Biomarkers
RecruitingPhase 2
A Clinical Trial of Extended (High) Treatment Dose Antibiotics in Combination With Methenamine Hippurate Compared to the Standard of Care (Either Prophylactic (Low) Dose Antibiotic Treatment or Methenamine Hippurate) in Females With Chronic Urinary Tract Infection
Chronic Urinary Tract Infection
Active, not recruitingObservational study
Characterization of Vaginal, Urinary and Fecal Microbiomes in Women With Recurrent Urinary Tract Infections
Urinary Tract Infections, Menopause
Not yet recruitingObservational study
Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)
Urinary Tract Infections
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Urinary Tract Infections and Patients With Suprabubic Catheter, run by Université Catholique de Louvain at 1 site in Belgium.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 10 Dec 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Françoise Van Bambeke, PhD (+32-2-764 ext. 7378, francoise.vanbambeke@uclouvain.be), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
collection of longitudinal E. coli to be used for fundamental research (time frame: collection till the end of 2024). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05826067, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Dec 2024.